Federal grants to Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. in Purchase, New York received $86.5 million in federal grants from fiscal 2021 to 2025, across 5 awards. Its largest program was Aging Research, with $86.5 million. In fiscal 2025 it was awarded $12.0 million.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$86.5 million
- Awards5
- Awarded in FY 2025$12.0 million
- Largest award$39.8 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 4 | $40.8 million |
| FY 2022 | 2 | $12.2 million |
| FY 2023 | 1 | $8.5 million |
| FY 2024 | 1 | $13.1 million |
| FY 2025 | 1 | $12.0 million |
Programs that fund Cognition Therapeutics, Inc.
| Program | Awards | Amount |
|---|---|---|
| Aging Research | 5 | $86.5 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $86.5 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Randomized double blind, placebo controlled, parallel group trial to evaluate the safety and efficacy of CT1812 in early alzheimer's disease over 18 months | Aging Research | January 12, 2021 | $39.8 million |
| A randomized, double-blind, placebo-controlled, parallel-group, phase 2 study to evaluate the safety and efficacy of CT1812 in subjects with dementia with lewy bodies - abstract: cognition therapeutics, inc. (COGRX) is developing CT1812 for neurodegenerative conditions, including dementia with lewy | Aging Research | May 6, 2021 | $29.5 million |
| A randomized, double-blind, placebo-controlled, parallel-group, phase II study to evaluate the safety and efficacy of CT1812 in subjects with mild to moderate alzheimer's disease | Aging Research | April 29, 2021 | $13.6 million |
| A pilot electroencephalography (EEG) study to evaluate the effect of CT1812 treatment on synaptic activity in subjects with mild to moderate alzheimer?s disease | Aging Research | January 12, 2021 | $2.1 million |
| Human ame study of CT1812, a small molecule in phase 2 clinical trials for the treatment of alzheimer's disease - project summary/abstract alzheimer's disease (AD) afflicts nearly six million people in the united states (u.s), and this number is expected to double by 2050. Disease modifying medical | Aging Research | April 30, 2021 | $1.6 million |
Questions people ask
How much federal grant money does Cognition Therapeutics, Inc. get?
$86.5 million in 5 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Cognition Therapeutics, Inc. the most?
The Department of Health and Human Services, with $86.5 million in 5 awards.
What is Cognition Therapeutics, Inc.'s largest federal grant?
$39.8 million under Aging Research, with its first action in the period on January 12, 2021. That counts only the money obligated in fiscal 2021 to 2025.
Other grant recipients in Purchase
- Family Services of Westchester Inc
- SUNY at Purchase College
- Manhattanville University
- The Research Foundation for the State University of New York
Largest federal grant recipients in New York · Federal grants in New York